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Iron-deficiency anaemia in pregnancy: the role of hepcidin
According to WHO, more than one in three pregnant 
women worldwide has iron-deficiency anaemia.1 
Because this disorder is associated with adverse 
maternal and neonatal outcomes if present at delivery, 
iron supplementation is recommended.2 However, 
treating iron-deficiency anaemia in pregnancy is not 
straightforward. Patients’ adherence to daily oral iron 
treatment regimens is low, most likely because of a 
high frequency of gastrointestinal side-effects,3 and 
oral iron has a low rate of systematic absorption.4 
Moreover, the optimum regimen of oral iron treat-
ment is unclear. Findings of a Cochrane review 
concluded that intermittent iron treatment could be as 
effective as daily iron supplementation for treatment 
of iron-deficiency anaemia in pregnancy.5 Although 
suboptimum, a one-size-fits-all approach for treatment 
of iron-deficiency anaemia in pregnancy with daily 
oral iron supplementation remains the international 
standard.6
In The Lancet Global Health, Amat Bah and colleagues 
assessed whether the treatment of iron-deficiency 
anaemia in pregnancy could be optimised by incor-
porating a physiologically plausible biomarker, hepcidin, 
into treatment algorithms.7 Amounts of hepcidin 
are suppressed by iron deficiency or iron-deficiency 
anaemia and are increased by high amounts in serum 
of iron or iron stores. This relationship is important 
because higher amounts of hepcidin decrease intestinal 
absorption of iron.8 Bah and colleagues posited that 
incorporating the amount of hepcidin into iron-
deficiency anaemia treatment algorithms would allow 
iron supplementation to be given only to those women 
who would more effectively absorb iron, ensuring 
that a treatment regimen with significant side-effects 
is restricted to those with the highest likelihood of 
receiving maximum benefit.
Bah and colleagues did a multicentre, three-arm, ran-
domised controlled trial of nearly 500 pregnant women 
in The Gambia and analysed whether one or both of two 
distinct hepcidin-based screen-and-treat approaches 
exceeded the non-inferiority margin when compared 
with conventional daily oral iron treatment, according 
to WHO guidelines.7 In both intervention groups, oral 
iron supplementation was given only to those women 
with amounts of hepcidin less than 2·5 µg/L; one group 
received WHO’s recommended daily supplementation 
of 60 mg of iron daily and the other received 30 mg 
of iron daily. The primary outcome was amount of 
haemoglobin at day 84 of treatment, and the non-
inferiority margin was set at –5·0 g/L.
Women in the intervention (screen-and-treat) 
groups received significantly less iron compared with 
women in the control (standard treatment) group, but 
the primary outcome did not exceed the preset non-
inferiority margin for either screen-and-treat algorithm. 
However, persistent anaemia was more common in 
the intervention groups compared with the control 
group. Bah and colleagues concluded that the screen-
and-treat algorithms incorporating hepcidin were 
less effective at treating iron-deficiency anaemia in 
pregnant women compared with standard care of daily 
iron supplementation, and they suggest their findings 
support current WHO guidelines regarding daily oral 
iron supplementation.1,6,7
Non-inferiority trials are becoming increasing com-
mon,9 and their interpretation might require some 
clarification for those accustomed to superiority trials.10 In 
this trial, the primary outcome fell within the prespecified 
non-inferiority threshold for both intervention groups 
compared with WHO’s recommended regimen; in other 
words, both proposed screen-and-treat algorithms were 
non-inferior to the standard treatment for the primary 
outcome. However, Bah and colleagues have concluded 
that hepcidin-based algorithms are less effective 
compared with standard treatment,7 which is not an 
appropriate conclusion for a non-inferiority trial.9,10
Why did the authors make this conclusion? Perhaps it 
is because the study’s most clinically relevant secondary 
outcome (the proportion of haemoglobin <11 g/dL 
at day 84) occurred with greater frequency with both 
screen-and-treat algorithms. Although it seems reason-
able to interpret these findings in secondary outcomes as 
inferior, it is important to note that second ary outcomes 
must be interpreted with caution in any trial. Moreover, 
the investigators did not specify non-inferiority margins 
for the secondary outcomes a priori. 
Furthermore, women in either intervention group had 
an increased frequency of anaemia at 84 days compared 
with at randomisation. This potentially counterintuitive 
finding has some possible explanations. First, the assay 
See Articles page e1564
Comment
e1477 www.thelancet.com/lancetgh   Vol 7   November 2019
used for weekly hepcidin testing in the intervention 
groups did not include information about actual 
iron absorption, instead reporting a predetermined 
hepcidin threshold to diagnose iron deficiency. Second, 
hepcidin might not be useful clinically for monitoring 
iron status among women who are adherent to iron 
supplementation. Bah and colleagues note these 
limitations.7 Finally, the iron supplementation used in 
this study might not have been administered in an ideal 
route. The rate of persistent anaemia in the control 
group approached 50% after 84 days of treatment, 
corresponding to only a 13% reduction in anaemia after 
nearly 3 months of daily iron supplementation. This 
important finding indicates that most patients failed 
treatment in a high-quality study in which participants 
were confirmed to adhere to recommended daily oral 
iron supplementation. Thus, the study inadvertently 
provides concerning evidence about the limited efficacy 
of oral iron treatment, however administered, for iron-
deficiency anaemia in pregnancy.
Although increasing evidence suggests that intravenous 
iron could be a more effective treatment with a good side-
effect profile, this route of administration was not tested 
in this study. In a meta-analysis of randomised trials, 
intravenous iron infusion had better haematological 
variables at delivery, improved perinatal outcomes, and 
fewer side-effects when compared with oral iron sup-
plementation for women with iron-deficiency anaemia in 
pregnancy.3 We agree with Bah and colleagues that cost-
effectiveness analyses and infrastructure development 
to overcome implementation barriers are needed in low-
income settings,7 but it is possible that iron infusions 
could help decrease morbidity related to iron-deficiency 
anaemia in pregnancy in both low-income and high-
income settings.
Although data from this trial do not support use of 
hepcidin-based approaches, Bah and colleagues should 
be commended for creating and testing novel treatment 
algorithms aimed at decreasing the side-effect burden of 
iron treatment without negatively affecting outcomes. 
Future studies should test other approaches and iron 
formulations to optimise treatment for iron-deficiency 
anaemia in pregnancy.
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